Wilson Sonsini Goodrich & Rosati advised investor Novo Holdings on the transaction. Obsidian Therapeutics, Inc. (Obsidian), a clinical-stage biotechnology company, announced it closed an oversubscribed $160.5...
Wilson Sonsini Goodrich & Rosati advised investor Novo Holdings on the transaction. Obsidian Therapeutics, Inc. (Obsidian), a clinical-stage biotechnology company, announced it closed an oversubscribed $160.5...
You must be a Standard 1 Year member to access this content.